Purpose: Human amniotic membrane is a highly abundant and easily accessible tissue that may potentially be an important chondrocyte carrier for cartilage regeneration in vivo. Objective: Study the feasibility of cryopreserved human amniotic membrane as a chondrocyte carrier for in vitro repair human articular cartilage injuries. Methods: Patches (6×6 cm) of cryopreserved human amniotic membrane were extended into a culture dish. Then human chondrocytes (5×10 5 cells) were cultured over the basal face of the amniotic membrane for 3−4 weeks until 80−90% confluence. These membranes were cut into pieces of 0.7×0.7 cm, and each of them was placed over a chondral defect (6 mm in diameter) of osteoarthritic cartilage with the basal layer facing the defect. The implants were cultured for 16 weeks. Evaluation of in vitro chondrocytes culture over the human amniotic membrane and repair, in in vitro models, of injured articular cartilage was carried out using histological (hematoxylin-eosin) and immunohistochemical (collagen type I and II) stainings. Results: Chondrocytes culture over the human amniotic membrane showed that cells grown over the basal layer, but they did not proliferate on the epithelial side. Histological techniques demonstrated that collagen type II but not type I was expressed in the chondrocytes culture on amniotic membrane. Valuation of repair, in 13 in vitro repair models, showed the formation of a new tissue on OA cartilage. Integration of new tissue with OA cartilage was excellent. Repair tissue expressed type II collagen in 100% of experiments, however collagen type I was present in 54% of cases. Conclusions: These results indicated that cryopreserved amniotic membrane can be used as support for chondrocytes proliferation in cell therapy to repair OA cartilage.
Purpose: Human amniotic membrane is a highly abundant and easily accessible tissue that may potentially be an important chondrocyte carrier for cartilage regeneration in vivo. Objective: Study the feasibility of cryopreserved human amniotic membrane as a chondrocyte carrier for in vitro repair human articular cartilage injuries. Methods: Patches (6×6 cm) of cryopreserved human amniotic membrane were extended into a culture dish. Then human chondrocytes (5×10 5 cells) were cultured over the basal face of the amniotic membrane for 3−4 weeks until 80−90% confluence. These membranes were cut into pieces of 0.7×0.7 cm, and each of them was placed over a chondral defect (6 mm in diameter) of osteoarthritic cartilage with the basal layer facing the defect. The implants were cultured for 16 weeks. Evaluation of in vitro chondrocytes culture over the human amniotic membrane and repair, in in vitro models, of injured articular cartilage was carried out using histological (hematoxylin-eosin) and immunohistochemical (collagen type I and II) stainings. Results: Chondrocytes culture over the human amniotic membrane showed that cells grown over the basal layer, but they did not proliferate on the epithelial side. Histological techniques demonstrated that collagen type II but not type I was expressed in the chondrocytes culture on amniotic membrane. Valuation of repair, in 13 in vitro repair models, showed the formation of a new tissue on OA cartilage. Integration of new tissue with OA cartilage was excellent. Repair tissue expressed type II collagen in 100% of experiments, however collagen type I was present in 54% of cases. Conclusions: These results indicated that cryopreserved amniotic membrane can be used as support for chondrocytes proliferation in cell therapy to repair OA cartilage. Purpose: Glucosamine (GlcN) supplements are taken by millions of osteoarthritic (OA) patients to ameliorate their symptoms and several large-scale studies have shown a benefit in slowing the progression of the disease. However, the molecular bases for the beneficial effect of GlcN are only beginning to be unravelled. Our aims were to determine whether glucosamine, added to the medium of cultured non-OA chondrocytes, affected the cytokine-induced expression of Il-1b. In addition, we investigated whether the NF-kB pathway is used in the signal transduction mechanisms involved in the cytokine-induced expression of Il-1b. Methods: Non-OA chondrocytes were isolated by sequential trypsin, hyaluronidase and collagenase digestion from osteoporotic patients who had sustained a fracture of the neck of femur. Previous studies had shown that these chondrocytes are suitable control chondrocytes, because the cells express chondrocytic genes, such as collagens types II, IX and XI, but do not express Il-1b. Cells were maintained in MEM with 5%FCS. Passage 2 cells were divided into the following experimental groups (n = 4 for each group): (I) control culture with no addition; (II) culture with GlcN alone (2 mM); (III) culture with TNF-a/OSM (10 ng/ml and 10 m/ml) and (IV) culture with TNF-a/OSM in presence of GlcN. In a further series, non-OA chondrocytes were cultured with TNF-a/OSM in presence of two compounds that inhibited the translocation of NF-kB to the nucleus. The first was NF-kB p65 (Ser 276) inhibitory peptide (50 mM) from Imgenex, the second was (E)-2-Fluoro-4'-methoxystilbene (0.2 mM), an analogue of Resveratrol from Merck. Media were changed twice-weekly, when the relevant factors were also added to II, II and IV. Cells were cultured until confluency (2−3 weeks) and semi-quantitative RT-PCR was carried out. Results: No expression of Il-1b was found in control cultures, with GlcN alone or with the NF-kB inhibitor alone. As expected, TNF-a/OSM induced expression of Il-1b in all cultures. However, the presence of GlcN completed prevented the cytokine-induced expression of Il-1b, as indicated by absence of the PCR band. Presence of the NF-kB translocation inhibitors reduced Il-1b expression, but did not abolish it completely, as suggested by reduced intensity of the PCR band.
Conclusions:
The present studies demonstrate that glucosamine has the capacity to inhibit the cytokine-induced expression of Il-1b. The glucosamine effect was greater than the effect of interfering with the NF-kB pathway of signal transduction. GlcN is a basic structural unit of chondroitin sulphate and hyaluronan of cartilage proteoglycan aggregates. Hence its beneficial effects were initially suggested to be due to stimulation of GAG synthesis, but the evidence for this mechanism is so far limited. Other studies have shown chondroprotective effects in vitro in that GlcN promoted the chondrogenic phenotype and inhibited MMP-13 expression. Il-1b is thought to play a major role in the progression of osteoarthritis, since Il-1b increases the expression of cartilage-degrading proteases. The present study suggests that GlcN treatment may have beneficial effects through prevention of Il-1b expression, which, in turn, might also reduce expression if its down-stream target genes. However, these are in vitro observations and need to be confirmed by in vivo studies.
THE SYNERGISTIC DRUG COMBINATION CRX-102

